Built on the authoritative federal record
The primary sources, named on every page.
These are the federal agencies whose public datasets Fonteum ingests and attributes — the issuing authorities, not customers or partners. Every figure on the site links back to one of them.
See the full source registry, with license and refresh cadence for each →
Reproducible by design
Every figure traces to its federal source.
14-tuple provenance
Every rendered fact ties to a source URL, dataset ID, snapshot date, row key, and SHA-256 — the full chain-of-custody record.
Reproducible SQL
Each study ships the exact query behind its figures, run against the cited federal snapshot. Re-run it yourself.
Daily reconciliation
Published counts are reconciled against the upstream federal datasets on a daily cadence, with drift logged.
Named medical review
Reviewed by Jennifer Montecillo, MD, medical reviewer. Non-practicing medical reviewer.
Two doors
Use the free API and open data
Query providers, facilities, sanctions, and quality scores — each field carrying its federal source. Self-serve, no call to start.
Talk to us
Managed pilots, enterprise terms, and audit-ready, signed attestation packages for compliance, risk, and research teams.
The substrate, by the numbers
Cross-source identity
National Provider Identifier 1003008533 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1003008533 | Registry identity — neurologist, taxonomy 2084N0400X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1003008533 | 69 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1003008533 | 79 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity f6d2eadb… | Canonical resolved node · 4 identifier(s) · 15 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $6,205 | 10 |
| Food and Beverage | $1,875 | 55 |
| Consulting Fee | $1,095 | 1 |
| Travel and Lodging | $70 | 3 |
| Manufacturer | Amount | Records |
|---|---|---|
| Eisai Inc. | $7,970 | 28 |
| Alexion Pharmaceuticals, Inc. | $261 | 8 |
| Sk Life Science, Inc. | $229 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Hizentra(Immun Glob G(Igg)/Pro/Iga 0-50) | 47 | $1,049,502 |
| Soliris(Eculizumab) | 12 | $638,729 |
| Gammagard Liquid(Immun Glob G(Igg)/Gly/Iga Ov50) | 13 | $275,029 |
| Gamunex-C(Immune Globul G/Gly/Iga Avg 46) | 21 | $228,085 |
| Austedo(Deutetrabenazine) | 29 | $176,422 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Novartis Pharmaceuticals Corporation (NJ) | cms_open_payments |
| ← pays | Alexion Pharmaceuticals, Inc. (MA) | cms_open_payments |
| ← pays | Biogen, Inc. (MA) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Eisai Inc. (NJ) | cms_open_payments |
| ← pays | Otsuka America Pharmaceutical, Inc. (MD) | cms_open_payments |
| ← pays | Emd Serono, Inc. (MA) | cms_open_payments |
| ← pays | Alnylam Pharmaceuticals Inc. (MA) | cms_open_payments |
| ← pays | Genentech Usa, Inc. (CA) | cms_open_payments |
| ← pays | Vanda Pharmaceuticals Inc. (DC) | cms_open_payments |
| ← pays | Lilly Usa, Llc (IN) | cms_open_payments |
| ← pays | Amneal Pharmaceuticals Llc (NJ) | cms_open_payments |
| ← pays | Argenx Us, Inc. (MA) | cms_open_payments |
| ← pays | Ucb, Inc. (GA) | cms_open_payments |
| ← pays | Sk Life Science, Inc. (NJ) | cms_open_payments |
Record history
Every field on this record is stored bitemporally — both when the fact was true in the world and when Fonteum recorded it. Open the time-travel view to reconstruct this record as of any past date, or to read each field with the source and dates behind it.
| 4 |
| Abbvie Inc. | $184 | 9 |
| Alnylam Pharmaceuticals Inc. | $117 | 1 |